ClinicalTrials.Veeva

Menu
T

Trustees of The University of Pennsylvania | Abramson Cancer Center

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Nivolumab
MK-6482
Pembrolizumab
Alectinib
MK-6482-005
Cobimetinib
VS-6063
Pertuzumab
CPI-613
Atezolizumab

Parent organization

This site is a part of Trustees of The University of Pennsylvania

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 27 total trials
Locations recently updated

A Study of Adjuvant V940 and Pembrolizumab in Renal Cell Carcinoma (V940-004) (INTerpath-004)

The primary objective of the study is to compare V940 plus pembrolizumab to placebo plus pembrolizumab in participants with renal cell carcinoma (RCC...

Enrolling
Renal Cell Carcinoma
Biological: Pembrolizumab
Biological: V940

The primary objective of this study is to compare belzutifan to everolimus with respect to progression-free survival (PFS) per Response Evaluation Cr...

Active, not recruiting
Carcinoma, Renal Cell
Drug: Everolimus
Drug: Belzutifan

This is a Phase 1/2 study of HST-1011, a CBL-B inhibitor, being developed for the treatment of patients with advanced solid tumors, who relapsed whil...

Enrolling
Relapsed Cancer
Solid Tumor, Adult
Drug: HST-1011
Biological: Cemiplimab

Phase 1, first-in-human, open label study of CAR macrophages in HER2 overexpressing solid tumors.

Active, not recruiting
Ovarian Neoplasms
Lung Cancer, Non-Small-Cell
Biological: CT-0508
Biological: Pembrolizumab

This study will compare DS 8201a to standard treatment.Participants must have HER2 breast cancer that has been treated before.Their cancer:* cannot b...

Active, not recruiting
Breast Cancer
Drug: Trastuzumab
Drug: Trastuzumab deruxtecan

The purpose of this study is to characterize the efficacy of ponatinib administered in 3 starting doses (45 mg, 30 mg, and 15 mg daily) in participan...

Active, not recruiting
Myeloid Leukemia, Chronic, Chronic Phase
Drug: Ponatinib

The purpose of this study is to evaluate the safety and efficacy of pembrolizumab (MK-3475) in the adjuvant treatment of adult participants who have...

Active, not recruiting
Renal Cell Carcinoma
Drug: Placebo
Biological: Pembrolizumab

The purpose of this study is to assess the safety, tolerability and preliminary efficacy of CC-94676 in men with progressive metastatic castration re...

Active, not recruiting
Prostatic Neoplasms
Drug: CC1083611
Drug: CC1083610

This research study is for Glioblastoma (GBM) patients who will be beginning Optune as part of their clinical care, which is a novel treatment that u...

Enrolling
Glioma Glioblastoma Multiforme
Tumor, Brain
Diagnostic Test: Whole Brain Spectroscopy Imaging Array Mapping Layout

Trial sponsors

Abramson Cancer Center at Penn Medicine logo
Merck Sharp & Dohme (MSD) logo
Celgene logo
Daiichi Sankyo logo
University of Pennsylvania logo
B
Bristol-Myers Squibb (BMS) logo
C
C
Genentech logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems